AUT00206

AUT00206 is a novel, orally active small molecule designed to selectively modulate Kv3.1 and Kv3.2 voltage-gated potassium channels. It is being developed primarily for the treatment of Fragile X syndrome and has received Orphan Drug Designation from the FDA for this indication. The drug has also been investigated in clinical trials for schizophrenia and other central nervous system (CNS) disorders characterized by neural hyperexcitability or dysfunction in dopaminergic signaling. Preclinical studies demonstrated efficacy in models of Fragile X syndrome with improvements in cognitive and behavioral function, while early-phase clinical trials have shown that it can modulate brain activity relevant to psychiatric disorders such as schizophrenia without significant safety concerns[1][2][6][9]. Its mechanism—modulation of Kv3 channels—represents a new approach distinct from traditional antipsychotics that target dopamine receptors.

Other names

AUT00206AUT-00206AUT 00206